Favoino E - Search Results

1

Clinical correlates of a subset of anti-fibroblast antibodies in systemic sclerosis.

Favoino E, Cipriani P, Liakouli V, Corrado A, Navarini L, Vomero M, Sisto A, Grembiale RD, Ciccia F, Cantatore FP, Ruscitti P, Giacomelli R, Perosa F. Favoino E, et al. Clin Immunol. 2023 Oct;255:109740. doi: 10.1016/j.clim.2023.109740. Epub 2023 Aug 14. Clin Immunol. 2023. PMID: 37586673 Free article.

2

The CSPG4-specific monoclonal antibody enhances and prolongs the effects of the BRAF inhibitor in melanoma cells.

Yu L, Favoino E, Wang Y, Ma Y, Deng X, Wang X. Yu L, et al. Among authors: favoino e. Immunol Res. 2011 Aug;50(2-3):294-302. doi: 10.1007/s12026-011-8232-z. Immunol Res. 2011. PMID: 21717063

3

Beta 2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide.

Perosa F, Luccarelli G, Prete M, Favoino E, Ferrone S, Dammacco F. Perosa F, et al. Among authors: favoino e. J Immunol. 2003 Aug 15;171(4):1918-26. doi: 10.4049/jimmunol.171.4.1918. J Immunol. 2003. PMID: 12902494

4

Human CD4 mimicry by anti-idiotypic monoclonal antibody 16D7 is based on a conformational epitope.

Perosa F, Favoino E, Caragnano MA, Dammacco F. Perosa F, et al. Among authors: favoino e. Immunol Lett. 2004 Sep;95(2):145-53. doi: 10.1016/j.imlet.2004.06.012. Immunol Lett. 2004. PMID: 15388254

5

CD20 mimicry by a mAb rituximab-specific linear peptide: a potential tool for active immunotherapy of autoimmune diseases.

Perosa F, Favoino E, Caragnano MA, Dammacco F. Perosa F, et al. Among authors: favoino e. Ann N Y Acad Sci. 2005 Jun;1051:672-83. doi: 10.1196/annals.1361.112. Ann N Y Acad Sci. 2005. PMID: 16127008

6

CD20: a target antigen for immunotherapy of autoimmune diseases.

Perosa F, Favoino E, Caragnano MA, Prete M, Dammacco F. Perosa F, et al. Among authors: favoino e. Autoimmun Rev. 2005 Nov;4(8):526-31. doi: 10.1016/j.autrev.2005.04.004. Autoimmun Rev. 2005. PMID: 16214090 Review.

7

Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor.

Perosa F, Favoino E, Caragnano MA, Dammacco F. Perosa F, et al. Among authors: favoino e. Blood. 2006 Feb 1;107(3):1070-7. doi: 10.1182/blood-2005-04-1769. Epub 2005 Oct 13. Blood. 2006. PMID: 16223774 Free article.

8

Biological therapy with monoclonal antibodies: a novel treatment approach to autoimmune disease.

Prete M, Perosa F, Favoino E, Dammacco F. Prete M, et al. Among authors: favoino e. Clin Exp Med. 2005 Dec;5(4):141-60. doi: 10.1007/s10238-005-0080-5. Clin Exp Med. 2005. PMID: 16362794 Review.

9

Identification of an antigenic and immunogenic motif expressed by two 7-mer rituximab-specific cyclic peptide mimotopes: implication for peptide-based active immunotherapy.

Perosa F, Favoino E, Vicenti C, Merchionne F, Dammacco F. Perosa F, et al. Among authors: favoino e. J Immunol. 2007 Dec 1;179(11):7967-74. doi: 10.4049/jimmunol.179.11.7967. J Immunol. 2007. PMID: 18025245

10

Rheumatic disorders as paraneoplastic syndromes.

Racanelli V, Prete M, Minoia C, Favoino E, Perosa F. Racanelli V, et al. Among authors: favoino e. Autoimmun Rev. 2008 May;7(5):352-8. doi: 10.1016/j.autrev.2008.02.001. Epub 2008 Feb 22. Autoimmun Rev. 2008. PMID: 18486921 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

48 results

Search Page